| Keith A. Katkin |
President and Chief Executive Officer
|
|
|
Keith A. Katkin joined AVANIR Pharmaceuticals in July of 2005 as Senior Vice President of Sales and Marketing and has served as a member of AVANIR's Executive Management Team. In March of 2007 Mr. Katkin was appointed President and CEO and elected as a member of the board of directors.
Prior to joining AVANIR, Mr. Katkin served as the Vice President, Commercial Development for Peninsula Pharmaceuticals, playing a key role in the management of the company. Additionally, Mr. Katkin's employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories.
Mr. Katkin received a Bachelor of Science degree in Business and Accounting from Indiana University and an M.B.A. in Finance from the Anderson School of Management at UCLA, graduating with honors. Mr. Katkin is also a Certified Public Accountant.
|
|
| Randall E. Kaye, M.D. |
Senior Vice President Clinical Research and Medical Affairs, Chief Medical Officer
|
|
|
Randall E. Kaye, M.D., joined AVANIR Pharmaceuticals in January 2006 in the newly created role of Vice President of Medical Affairs. Since November 2006 he held the position of Vice President, Clinical and Medical Affairs and in February 2007 was promoted to Senior Vice President Clinical Research and Medical Affairs, Chief Medical Officer. Dr. Kaye's focus is on providing leadership and vision to the Clinical, Regulatory and Medical Affairs areas and to support the commercialization of new products from a medical, scientific, regulatory, technical and quality perspective.
Immediately prior to joining AVANIR, Dr. Kaye was the Vice President of Medical Affairs for Scios Inc., a division of Johnson & Johnson, where he built and integrated a Medical Affairs department consisting of 80 professionals. Prior to joining Johnson & Johnson, Dr. Kaye recruited and managed the Medical Affairs department for InterMune Inc. Previously, Dr. Kaye served for nearly a decade in a variety of Medical Affairs and Marketing positions for Pfizer Inc.
Dr. Kaye earned his Doctor of Medicine, Masters in Public Health and Bachelor of Science degrees at George Washington University in Washington, D.C. and was a Research Fellow in Allergy and Immunology at Harvard Medical School. |
|
| Eric S. Benevich |
Vice President, Communications
|
|
|
Eric S. Benevich joined Avanir Pharmaceuticals in July 2005 as Senior Director of Marketing. In August 2007, he was promoted to Vice President of Communications and is responsible for all external communications as well as commercial planning and market development activities for Avanir’s portfolio products. During his tenure at Avanir, Mr. Benevich helped build the Avanir commercial infrastructure and successfully relaunched FazaClo ® , more than doubling its sales in less than one year after Avanir acquired the product.
Prior to joining Avanir, Mr. Benevich previously served as the Senior Director of Marketing for Peninsula Pharmaceuticals. Prior to his tenure at Peninsula Pharmaceuticals, Mr. Benevich held several Marketing positions with Amgen Inc., a global biotechnology company. In addition, Mr. Benevich held several commercial roles at Astra Merck in Sales, Market Research and Brand Marketing. With over 16 years experience in the pharmaceutical industry, Mr. Benevich has been involved in marketing some of the most successful blockbuster prescription products including Prilosec ® , EPOGEN ® and Enbrel ® .
Mr. Benevich graduated from Washington State University with a degree in International Business and has completed several MBA courses at Villanova University.
|
|
| Gregory J. Flesher |
Vice President, Business Development
|
|
|
Gregory J. Flesher joined Avanir Pharmaceuticals in June 2006 as Senior Director of Commercial Strategy and in November 2006 assumed the additional responsibility for Business Development and Portfolio Planning. In these roles, Mr. Flesher was responsible for Zenvia lifecycle planning and new product development as well as the integration of Alamo Pharmaceuticals following their acquisition. In August 2007 he was promoted to Vice President of Business Development with responsibility for management of all ongoing and new partnerships, in/outlicensing activities, strategic planning, and Avanir’s intellectual property portfolio.
Prior to joining Avanir, he served as a Sales Director from 2004 to 2006 and as Director of Pulmonary & Infectious Disease Marketing from 2002 to 2004 at InterMune, Inc., a biopharmaceutical company. Prior to his tenure at InterMune, Mr. Flesher held Oncology and Nephrology marketing positions with Amgen Inc., a global biotechnology company. Mr. Flesher also has global marketing and clinical development experience from Eli Lilly and Company.
Mr. Flesher graduated from Purdue University with a degree in Biology and has completed his doctorate coursework in Biochemistry and Molecular Biology at Indiana University School of Medicine. |
|
| Christine G. Ocampo |
Vice President, Finance
|
|
|
Christine G. Ocampo joined Avanir Pharmaceuticals in March of 2007 as the Corporate Controller. As Vice President of Finance, Ms. Ocampo is responsible for all accounting operations, budgeting, cash management, SEC reporting, and corporate compliance. During her tenure at Avanir Ms. Ocampo was an integral part of the successful divestiture of FazaClo® as well as leading the strategic consolidation of the corporate finance function.
Prior to joining the Company, Ms. Ocampo served as Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer and Secretary of Cardiogenesis Corporation from November 2003 until April 2006. From 2001 to November 2003, Ms. Ocampo served in the role of Vice President and Corporate Controller at Cardiogenesis. Prior to first joining Cardiogenesis in April 1997, Ms. Ocampo held a management position in Finance at Mills-Peninsula Health Systems in Burlingame, CA, and spent three years as an auditor for Ernst & Young LLP.
Ms. Ocampo graduated with a Bachelors of Science in Accounting from Seattle University and became a licensed Certified Public Accountant in 1996.
|
|
